Thu, Mar. 24, 9:55 AM
- StemCells (STEM -2.8%) Q4 results: Revenues: $28M (-96.8%); R&D Expense: $5.9M (-10.6%); SG&A: $2.3M (-42.5%); Operating Loss: ($8.5M) (+12.4%); Net Loss: ($9M) (+10.9%); Loss Per Share: ($0.08) (+46.7%); Non-GAAP Loss Per Share: ($0.07) (+50.0%).
- FY2015 results: Revenues: $0.1M (-90.0%); R&D Expense: $27.1M (+26.0%); SG&A: $9.3M (-10.6%); Operating Loss: ($36.7M) (-18.8%); Net Loss: ($36.4M) (-12.7%); Loss Per Share: ($0.38) (+26.9%); Non-GAAP Loss Per Share: ($0.33) (-31.3%); Quick Assets: $12.1M (-51.6%).
- No guidance given.
Wed, Mar. 23, 4:13 PM
Wed, Mar. 9, 11:03 AM
- StemCells (STEM -33.3%) is down on a 16x surge in volume in response to its announcement of the pricing of its public offering of common stock and warrants.
- The offering appears to be units, with each unit comprised of one share of common stock at $0.30 per share, a two-year Series A warrant to purchase 1/2 a share of common at $0.30 and a five-year Series B warrant to purchase 3/4 of a share of common at $0.42. Gross proceeds are expected to be ~$8.1M which implies a 27M-share offering.
- Underwriters over-allotment is an additional ~4M shares of stock and/or warrants to purchase up to ~5M shares of stock.
- Net proceeds will fund general corporate purposes, including working capital, capex and R&D. Closing date is March 14.
Fri, Jan. 15, 7:33 AM
- In a regulatory filing, StemCells (NASDAQ:STEM) discloses that it has promoted President & COO Dr. Ian Massey to President & CEO succeeding Martin McGlynn, who will resign effective January 17. Dr. Massey, who has been with the firm since March 2015, joined the company from BioTie Therapies where he was COO and President of U.S. Operations.
Dec. 23, 2015, 10:26 AM
- Buoyed by encouraging clinical results, StemCells (STEM -11.3%) announces a strategic realignment to fully focus its resources on its proprietary HuCNS-SC platform for the treatment of spinal cord injury (SCI).
- The plan, expected to trim $20M in costs over the next two years, includes the suspension of the Phase 2 Radiant study in geographic atrophy of age-related macular degeneration while the company seeks a development partner. It also includes a 25% workforce reduction that will be completed by the end of January. StemCells will book a $400K charge in Q1 for one-time employee termination costs.
- The freed-up funds will allow it to accelerate the completion of the ongoing Phase 2 Pathway Study and the commencement of a Phase 3 trial in SCI.
Nov. 18, 2015, 4:55 PM
- In a webcast this afternoon, StemCells (NASDAQ:STEM) presented six-month interim results from the first cohort in its Phase 2 proof-of-concept Pathway Study evaluating its HuCNS-SC platform (purified human neural stem cells) in cervical spinal cord injury, an open-label dose escalation arm used to determine the cell dose for the second cohort of the trial. Final results from this cohort are expected in Q2 2016.
- Dose escalation from 15M to 30M to 40M cells. Dose of 40M cells was well tolerated and will be the dose for the second cohort. Safety profile is acceptable. Five of six patients in the first cohort showed improved upper extremity muscle strength and four showed improved function in dexterity.
- The second cohort, expected to be 40 participants with complete loss of motor function below the point of injury, will be a randomized, single-blind study statistically powered to show efficacy. Final results from the study are expected in 2017.
- Shares are up 19% after hours on robust volume.
Nov. 2, 2015, 4:40 PM
- StemCells (NASDAQ:STEM): Q3 EPS of -$0.09 in-line.
- Revenue of $37K (-54.9% Y/Y)
Aug. 6, 2015, 4:41 PM
- StemCells (NASDAQ:STEM): Q2 EPS of -$0.08 beats by $0.01.
- Revenue of $0.03M (+50.0% Y/Y) in-line.
- Shares -2.62%.
Jul. 20, 2015, 10:37 AM
- The first geographic atrophy (GA) patient has been transplanted with StemCells' (STEM +2%) proprietary HuCNS-SC neural stem cells in its Phase 2 clinical trial in dry age-related macular degeneration. GA is the most advanced form of the condition.
- The primary endpoint of the 63-subject proof-of-concept study, called RADIANT, is the change in GA area as measured by fundus autofluorescence at month 12. The estimated completion date of the trial is December 2017.
- Age-related macular degeneration is characterized by the loss of photoreceptors (rods and cones) from the central part of the retina (macula). It typically manifests in older people and is the leading cause of severe vision loss and legal blindness in adults over the age of 55.
Jun. 4, 2015, 11:08 AM
- StemCells (STEM +1.4%) announces the enrollment its first patient in Cohort 2 of its Phase 2 Pathway Study, designed to assess the efficacy of its HuCNS-SC (purified human neural stem cells) for the treatment of cervical spinal cord injury. Cohort 2 will enroll 40 patients and will constitute the single-blind control arm. The primary endpoint is the change in motor strength from baseline in the upper extremities.
- The Pathway Study has three cohorts: Cohort 1 is a dose-escalation arm involving six patients, Cohort 2 will assess efficacy in 40 patients and Cohort 3 is an optional open label arm involving six patients with less severe injuries. The trial will follow the participants for one year. Enrollment in Cohort 1 was completed in April.
May 26, 2015, 1:43 PM
- Blueprint Medicines (BPMC -1.8%) initiated with Outperform rating and $41 (37% upside) price target by Wedbush.
- Applied DNA Sciences (APDN -1.6%) initiated with Speculative Buy rating and $5 (100% upside) price target by Benchmark.
- StemCells (STEM +1.2%) initiated with Buy rating with $2 (190% upside) price target by Cantor Fitzgerald.
- Horizon Pharma (HZNP -0.4%) initiated with Outperform rating and $37 (16% upside) price target by Leerink Swann.
- Uniqure (QURE +1.7%) initiated with Outperform rating and $47 (74% upside) price target by Oppenheimer.
- Sharps Compliance (SMED -2.3%) initiated with Buy rating and $8 (43% upside) price target by Stifel Nicolaus.
- Barclays initiates coverage on four stocks: Overweight ratings on three: Alkermes plc (ALKS -2.9%) with $74 (23% upside) price target; Esperion Therapeutics (ESPR -3%) with $150 (43% upside) price target and Intercept Pharmaceuticals (ICPT +0.6%) with a $425 (62% upside) price target and an Equal Weight rating on Trevena (TRVN) with an $11 (62% upside) price target.
May 19, 2015, 1:18 PM
- StemCells (STEM -0.7%) initiated with Buy rating and $1 (67% upside) price target by H.C. Wainwright.
- Biodel (BIOD -0.9%) initiated with Buy rating and $5 (339% upside) price target by Roth Capital.
- Antares Pharma (ATRS -0.2%) initiated with Overweight rating and $3.50 (64% upside) price target by Piper Jaffray.
- Pfenex (PFNX -3.8%) initiated with Overweight rating and $28 (83% upside) price target by Barclays.
May 6, 2015, 10:02 AM
- StemCells (STEM +1.4%) Q1 results: Revenues: $21K (-12.5%); R&D Expense: $6.3M (+37.0%); SG&A: $2.7M (+22.7%); Operating Loss: ($9M) (-32.4%); Net Loss: ($9.4M) (-23.7%); Loss Per Share: ($0.14) (unch); Quick Assets: $14.1M (-43.6%); CF Ops: ($8.9M) (-36.9%).
- No guidance given.
May 5, 2015, 5:00 PM
- StemCells (NASDAQ:STEM): Q1 EPS of -$0.11 beats by $0.03.
- Revenue of $0.02M (flat Y/Y)
- Shares +1.1% AH.
Apr. 24, 2015, 11:57 AM
- StemCells (STEM -28.4%) prices its public offering of common stock and warrants at $0.70 for the combination. The exercise price of the five-year warrants is $0.85. The number of shares is not disclosed but the expected gross proceeds of ~$25M implies 35.7M.
- Underwriters over-allotment is an additional 5,357,250 shares and warrants to purchase an additional 4,017,938 shares. Closing date is April 29.
Apr. 23, 2015, 4:59 PM
StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies;... More
Country: United States